- Home
- EB vs SLS Comparison
EB vs SLS Comparison
Compare EB & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EB
- SLS
- Stock Information
- Founded
- EB 2003
- SLS 2012
- Country
- EB United States
- SLS United States
- Employees
- EB N/A
- SLS N/A
- Industry
- EB EDP Services
- SLS Biotechnology: Pharmaceutical Preparations
- Sector
- EB Technology
- SLS Health Care
- Exchange
- EB Nasdaq
- SLS Nasdaq
- Market Cap
- EB 226.8M
- SLS 233.7M
- IPO Year
- EB 2018
- SLS N/A
- Fundamental
- Price
- EB $2.23
- SLS $2.14
- Analyst Decision
- EB Buy
- SLS Strong Buy
- Analyst Count
- EB 2
- SLS 1
- Target Price
- EB $5.25
- SLS $7.00
- AVG Volume (30 Days)
- EB 457.7K
- SLS 3.2M
- Earning Date
- EB 11-06-2025
- SLS 11-12-2025
- Dividend Yield
- EB N/A
- SLS N/A
- EPS Growth
- EB N/A
- SLS N/A
- EPS
- EB N/A
- SLS N/A
- Revenue
- EB $300,856,000.00
- SLS N/A
- Revenue This Year
- EB N/A
- SLS N/A
- Revenue Next Year
- EB $9.53
- SLS N/A
- P/E Ratio
- EB N/A
- SLS N/A
- Revenue Growth
- EB N/A
- SLS N/A
- 52 Week Low
- EB $1.81
- SLS $0.77
- 52 Week High
- EB $4.12
- SLS $2.29
- Technical
- Relative Strength Index (RSI)
- EB 33.81
- SLS 71.14
- Support Level
- EB $2.33
- SLS $1.89
- Resistance Level
- EB $2.44
- SLS $2.29
- Average True Range (ATR)
- EB 0.10
- SLS 0.13
- MACD
- EB -0.03
- SLS 0.04
- Stochastic Oscillator
- EB 1.13
- SLS 82.88
About EB Eventbrite Inc.
Eventbrite Inc is a self-service ticketing and experience technology platform that serves event creators. The company's two-sided marketplace connects creators and consumers every month to share their passions, artistry, and causes through live experiences. Creators use its self-service ticketing and marketing tools to plan, promote, and sell tickets to their events, and event seekers use its website and mobile application to discover and purchase tickets to experiences. Geographically, it generates maximum revenue from the United States. The company generates revenues principally from service fees and payment processing fees from the sale of paid tickets on its platform.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.